News headlines about Biolase (NASDAQ:BIOL) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biolase earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 45.1252083135468 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of research analysts have weighed in on the company. Singular Research assumed coverage on Biolase in a report on Tuesday, April 25th. They set a “buy” rating and a $2.50 target price for the company. ValuEngine lowered Biolase from a “hold” rating to a “sell” rating in a report on Monday.
Biolase (BIOL) traded down 2.25% on Friday, reaching $0.87. The company’s stock had a trading volume of 39,573 shares. The stock’s market cap is $58.86 million. The stock has a 50-day moving average of $0.96 and a 200-day moving average of $1.25. Biolase has a one year low of $0.79 and a one year high of $1.98.
Biolase (NASDAQ:BIOL) last posted its quarterly earnings data on Wednesday, May 3rd. The medical technology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.03. Biolase had a negative return on equity of 65.77% and a negative net margin of 29.44%. The company had revenue of $10.87 million during the quarter. On average, analysts predict that Biolase will post ($0.14) EPS for the current fiscal year.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
